Les Laboratoires Servier SAS (Servier) is dedicated to advancing therapeutic solutions in oncology, cardio-metabolism, venous diseases, and neurology. The company’s research and development efforts are directed at areas where treatment options are limited, such as digestive cancers (gastric, pancreatic, and cholangiocarcinoma), gliomas, hematological cancers (acute myeloid leukemia, acute lymphoblastic leukemia, and lymphomas), and pediatric cancers.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Servier's research and development (R&D) initiatives are characterized by a strong focus on innovation and collaboration, aiming to address unmet medical needs across various therapeutic areas. The company's R&D is primarily focused on oncology, neurology, and cardio-metabolism and venous diseases. In oncology, the emphasis is on precision medicine and targeted therapies, particularly for digestive cancers, brain tumors, and hematological cancers. In neurology, the focus is on rare neurological disorders, leveraging expertise in small molecules, monoclonal antibodies, and antisense oligonucleotides. For cardio-metabolism and venous diseases, the development of Single Pill Combinations is a key strategy to improve therapeutic adherence. Servier’s diverse pipeline covers several therapeutic areas, including solid tumors, blood diseases, neurology, and immuno-inflammation. Key projects include treatments for solid tumors and combinations targeting non-small cell lung cancer and gastric cancer, as well as advancing therapies like Calaspargase pegol and Cema-Cel for lymphoma and leukemia. In neurology, Servier is exploring LRRK2 inhibitors for Parkinson’s disease, alongside autoimmune disease treatments in immuno-inflammation. As of 2025, its R&D pipeline has 62 projects, including 41 in clinical development. The company operates six R&D centers located in France, the US, Denmark, and Hungary, along with three clinical hubs in North & South America, Europe, and Asia-Pacific. Servier emphasizes collaborative innovation, engaging in over 60 partnerships and research collaborations worldwide, with strategic partnerships with tech companies like Google Cloud and biotech firms such as Aitia and Owkin to harness artificial intelligence and digital tools to accelerate therapeutic innovation. As of October 2025, Servier holds 6,413 patent applications and active patents.